An amylin analog used as a challenge test for Alzheimer's disease.

Zhu H, Stern RA, Tao Q, Bourlas A, Essis MD, Chivukula M, Rosenzweig J, Steenkamp D, Xia W, Mercier GA, Tripodis Y, Farlow M, Kowall N, Qiu WQ

Alzheimer's & dementia (New York, N. Y.)1 Jan 2017Cited by 13 (Europe PMC)

PMID28503657PMCIDPMC5424531DOI10.1016/j.trci.2016.12.002PepBankPUB-28503657

Read at source PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialSafety outcome
In nondiabetic subjects, no participant developed hypoglycemia after pramlintide injection.
In plain wordsNo nondiabetic participant developed low blood sugar after pramlintide injection.
Peptide
Pramlintide (Symlin)
Outcome
Not applicableHypoglycemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
60 μg · subcutaneous · single injectionAs given in this study (human).
Source sentences
Summary
None of the participants developed hypoglycemia after the injection of pramlintide.
1 context sentence(design, population, supporting numbers)
Summary · context
We administered a single subcutaneous injection of 60 μg of pramlintide to nondiabetic subjects under fasting conditions.
Report a problemFND-2850365701
02HumanNon-randomized trialActivity measurement
Pramlintide induced a significant plasma amyloid-β surge in Alzheimer's disease subjects but not controls.
In plain wordsPramlintide raised blood amyloid-β in people with Alzheimer's disease but not controls.
Peptide
Pramlintide (Symlin)
Outcome
IncreasePlasma amyloid-β
Study
n: not reported in source
Outcome group
Aging markers · Nervous system and cognition
Studied dose
60 μg · subcutaneous · single injectionAs given in this study (human).
Source sentences
Summary
The pramlintide challenge induced a significant surge of amyloid-β peptide and a decrease in total tau in the plasma of AD subjects but not in control participants.
1 context sentence(design, population, supporting numbers)
Summary · context
We administered a single subcutaneous injection of 60 μg of pramlintide to nondiabetic subjects under fasting conditions.
Report a problemFND-2850365702
03HumanNon-randomized trialActivity measurement
Pramlintide decreased plasma total tau in Alzheimer's disease subjects but not controls.
In plain wordsPramlintide lowered blood total tau in people with Alzheimer's disease but not controls.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePlasma total tau
Study
n: not reported in source
Outcome group
Aging markers · Nervous system and cognition
Studied dose
60 μg · subcutaneous · single injectionAs given in this study (human).
Source sentences
Summary
The pramlintide challenge induced a significant surge of amyloid-β peptide and a decrease in total tau in the plasma of AD subjects but not in control participants.
1 context sentence(design, population, supporting numbers)
Summary · context
We administered a single subcutaneous injection of 60 μg of pramlintide to nondiabetic subjects under fasting conditions.
Report a problemFND-2850365703
04HumanNon-randomized trialActivity measurement
Pramlintide increased interleukin 1 receptor antagonist, distinguishing Alzheimer's disease subjects from controls.
In plain wordsPramlintide raised interleukin 1 receptor antagonist in a response that distinguished Alzheimer's disease subjects from controls.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseInterleukin 1 receptor antagonist
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
60 μg · subcutaneous · single injectionAs given in this study (human).
Source sentences
Summary
The pramlintide injection provoked an increase in interleukin 1 receptor antagonist and a decrease in retinol-binding protein 4, which separates AD subjects from control subjects.
1 context sentence(design, population, supporting numbers)
Summary · context
We administered a single subcutaneous injection of 60 μg of pramlintide to nondiabetic subjects under fasting conditions.
Report a problemFND-2850365704
05HumanNon-randomized trialActivity measurement
Pramlintide decreased retinol-binding protein 4, distinguishing Alzheimer's disease subjects from controls.
In plain wordsPramlintide lowered retinol-binding protein 4 in a response that distinguished Alzheimer's disease subjects from controls.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseRetinol-binding protein 4
Study
n: not reported in source
Outcome group
Aging markers · Nervous system and cognition
Studied dose
60 μg · subcutaneous · single injectionAs given in this study (human).
Source sentences
Summary
The pramlintide injection provoked an increase in interleukin 1 receptor antagonist and a decrease in retinol-binding protein 4, which separates AD subjects from control subjects.
1 context sentence(design, population, supporting numbers)
Summary · context
We administered a single subcutaneous injection of 60 μg of pramlintide to nondiabetic subjects under fasting conditions.
Report a problemFND-2850365705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.